共 50 条
- [1] Vedolizumab for the Treatment of Moderately to Severely Active Ulcerative Colitis [J]. PHARMACOTHERAPY, 2015, 35 (04): : 412 - 423
- [8] Cost per clinical outcomes with biologics for the treatment of moderately to severely active ulcerative colitis [J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 : S239 - S240